Canadian consensus conference on the management of viral hepatitis

Canadian Journal of Gastroenterology

Volumn 14, Issue SUPPL. B, 2000, Pages

  Sherman, M ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Canadian Association for Study of the Liver (CASL); Consensus conference; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Vaccination; Viral hepatiti

Indexed keywords

EID: 24044522943     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (125)

1. Wong WW, Minuk GY. A cross-sectional seroepidemiologic survey of chronic hepatitis B virus infections in Southeast Asian immigrants residing in a Canadian urban centre. Clin Invest Med 1994:17:443-7.
2. Sweet LE, Brown MG, Lee SH, Liston RM, MacDonald MA, Forward KR. Hepatitis B prenatal screening survey, Nova Scotia, 1990-1991. Can J Public Health 1993;84:279-82.
3. Chernesky MA, Blajchman MA, Castriciano S, Basbaum J, Spivak C, Mahony JB. Analysis of a pregnancy-screening and neonatal-immunization program for hepatitis B in Hamilton, Ontario, Canada, 1977-1988. J Med Virol 1991;35:50-4.
4. Delage G, Montplaisir S, Remy-Prince S, Pierri E. Prevalence of hepatitis B virus infection in pregnant women in the Montreal area. Can Med Assoc J 1986;134:897-901.
5. Minuk GY, Nicolle LE, Postl B, Waggoner JG, Hoofnagle JH. Hepatitis virus infection in an isolated Canadian Inuit (Eskimo) population. J Med Virol 1982;10:255-64.
6. Baikie M, Ratnam S, Bryant DG, Jong M, Bokhout M. Epidemiologic features of hepatitis B virus infection in Northern Labrador. Can Med Assoc J 1989;141:791-5.
7. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82.
8. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130-3.
9. Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B patterns and natural history. J Clin Gastroenterol 1990;12:562-8.
10. Fattovich G, Brollo L, Alberti A, et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990;10:141-6.
11. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus infection. Incidence, predisposing factors and etiology. J Hepatol 1990;10:29-34.
12. Lok AS, Lai CL, Wu PC, Leung EK, Lam T. Spontaneous hepatitis B e antigen to antibody serconversionand reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92:1839-43.
13. Fattovich G, Rigge M, Brollo L, et al. Clinical, virologic and histologic outcome following serconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-72.
14. de Franchis R, Meucci G, Vecchi M, et al. The natural history of symptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-4.
15. Fattovich G, Guistina G, Sanches-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998;93:896-900.
16. Koh KC, Lee HS, Kim CY. Universal emergence of precore mutant hepatitis B virus along with seroconversion to anti-HBe irrespective of subsequent activity of chronic hepatitis B. Korean J Intern Med 1994;9:61-6.
17. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multi-center study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994;21:656-66.
18. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
19. Fattovich G, Brollo L, Guistina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:194-8.
20. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981;ii:1129-33.
21. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
22. Heathcote J, Schalm S, Ciancara J, et al. Lamivudine and intron A combination treatment in chronic hepatitis B infection. Hepatology 1998;28(Suppl):43.
23. Schiff E, Karayalcin S, Grimm I, et al. A placebo-controlled study of lamivudine and interferon alpha 2 b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998;28(Suppl):43.
24. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7.
25. Di Bisceglie AM, Fong TL, Fried MW, et al. A randomized controlled trial of recombinant alpha interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-92.
26. Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomized controlled trial of recombinant interferon alpha-2 in Chinese patients with chronic hepatitis B infection. Lancet 1988;ii:298-302.
27. Lai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha-2 interferon in Chinese HBsAg-carrier children. Lancet 1987;ii:877-80.
28. Krogsgaard K, Bindslev N, Christensen E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994;21:646-55.
29. Thomas HC, Lok AS, Carreno V, et al. Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepatol 1994;1:139-48.
30. Brook MG, McDonald JA, Karayiannis P, et al. Randomized controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989;30:1116-22.
31. Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995;108:165-71.
32. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-3.
33. Lok AS, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepatol 1998;5:171-8.
34. Fattovich G, McIntyre G, Thursz M, et al. Hepatitis B virus precore/core variation and interferon therapy. Hepatology 1995;22:1355-62.
35. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-96.
36. Picardi M, Selleri C, De Rosa G, Raiola A, Pezzullo L, Rotoli B. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 199;21:1267-9.
37. Brind AM, Bennett MK, Bassendine MF. Nucleoside analogue therapy in fibrosing cholestatic hepatitis - a case report in an HBsAg positive renal transplant recipient. Liver 1998;18:134-9.
38. Lok AS, Lindsay I, Scheuer PJ, Thomas HC. Clinical and histological features of delta infection in chronic hepatitis B virus carriers. J Clin Pathol 1985;38:530-3.
39. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94.
40. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-16.
41. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995;47:225-30.
42. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995;109:540-6.
43. Bortolotti F, Faggion S, Con P. Natural history of chronic viral hepatitis in childhood. Acta Gastroenterol Belg 1998 61:198-201.
44. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-95.
45. Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998;143:2493-503.
46. Murphy DG, Willems B, Delage G, et al. Hepatitis C virus genotypes in patients and blood donors. Can Commun Dis Rep 1995;21:129-32.
47. Bernier L, Willems B, Delage G, Murphy DG. Indentification of numerous hepatitis C virus genotypes in Montreal, Canada. J Clin Microbiol 1996;34:2815-8.
48. Altamirano M, Delaney A, Wong A, Maronstenmaki J, Pi D. Identification of hepatitis C virus genotypes among hospitalized patients in British Columbia, Canada. J Infect Dis 1995;171:1034-8.
49. Andonov A, Chaudhari RK. Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Microbiol 1994;32:2031-4.
50. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
51. Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998;29:12-9.
52. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
53. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-9.
54. Pol S, Lamothe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-50.
55. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22.
56. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
57. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-90.
58. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378-86.
59. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
60. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72.
61. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
62. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
63. Piazza M, Sagliocca L, Tosone G, et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997;157:1537-44.
64. Kao JH, Liu CJ, Chen PJ, et al. Interspousal transmission of GB virus-C/hepatitis G virus: a comparison with hepatitis C virus. J Med Virol 1997;53:348-53.
65. Comandini UV, Tossini G, Longo MA, Ferri F, Cuzzi G, Noto P. Sporadic hepatitis C virus infection: a case-control study of transmission routes in a selected hospital sample of the general population in Italy. Scand J Infect Dis 1998;30:11-5.
66. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991;115:764-8.
67. Thomas DL, Zenilman JM, Alter HJ, et al. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994;169:990-5.
68. Akahane Y, Kojima M, Sugai Y, et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994;120:748-52.
69. Caporaso N, Ascione A, Stroffolini T. Spread of hepatitis C virus infection within families. Investigators of an Italian Multicenter Group. J Viral Hepatol 1998;5:67-72.
70. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1997;330:744-50.
71. Zanetti AR, Tanzi E, Romano L, et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998;41:208-12.
72. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345:1209-11.
73. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998;177:1480-8.
74. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
75. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-7.
76. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
77. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998;352:1426-32.
78. Laursen AL, Scheibel E, Ingerslev J, et al. Alpha interferon therapy in Danish hemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon alpha 2b treatment. Haemophilia 1998;4:25-32.
79. Rumi MG, Santagostino E, Morfini M, et al. A multicenter controlled randomized open label trial of interferon alpha 2b treatment of anti-human immunodeficiency virus-negative hemophiliac patients with chronic hepatitis C. Hepatitis Study Group of the Italian Hemophilia Centers. Blood 1997;89:3529-33.
80. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
81. Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
82. Garcia-Monzon C, Jara P, Fernandez-Bermejo M, et al. Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology 1998;28:1696-701.
83. Iorio R, Pensati P, Porzio S, Fariello I, Guida S, Vegnente A. Lymphoblastoid interferon alfa treatment in chronic hepatitis C. Arch Dis Child 1996;74:152-6.
84. Bortolotti F, Giacchino R, Vajro P, et al. Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology 1995;22:1623-7.
85. Viladomiu L, Genesca J, Esteban JI, et al. Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology 1992;15:767-9.
86. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994;21:831-6.
87. Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
88. Crespo J, Lozano JL, de la Cruz F, et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 1994;89:1147-51.
89. Chan CY, Lee SD, Wu JC, et al. Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B. Scand J Infect Dis 1991;23:421-4.
90. Sato S, Fujiyama S, Tanaka M, et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994;21:159-66.
91. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
92. Fong TL, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991;14:64-7.
93. Benvengu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994;74:2442-8.
94. Pontisso P, Ruvoletta MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993;105:1529-33.
95. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
96. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996;31:552-8.
97. Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepatol 1995;2:39-45.
98. Hess G, Rossol S, Voth R, et al. Treatment of patients with chronic type B hepatitis and concurrent human immunodeficiency virus infection with a combination of interferon alpha and azidothymidine: a pilot study. Digestion 1989;43:56-9.
99. Macias J, Pineda JA, Leal MA, et al. Influence of hepatitis C infection on the mortality of antiretroviral-treated patients with HIV disease. Eur J Clin Microbiol Infect Dis 1998;17:167-70.
100. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci 1996;41:1265-72.
101. Soriano V, Garcia-Samaniego J, Bravo R, et al. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group. J Infect 1995;31:9-13.
102. Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998;26:16-9.
103. Mauss S, Heintges T, Adams O, Albrecht H, Niederau C, Jablonowski H. Treatment of chronic hepatitis C with interferon-alpha in patients infected with the human immunodeficiency virus. Hepatogastroenterology 1995;42:528-34.
104. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comite des Anti-Viraux. J Infect Dis 1992;165:723-6.
105. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B related sequelae. Prospective study of 1400 hepatitis B surface antigen positive Alaskan native carriers. Arch Intern Med 1990;150:1051-4.
106. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;106:1000-5.
107. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
108. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
109. Heyward WL, Lanier AP, McMahon BJ, Fitzgerald MA, Kilkenny S, Paprocki TR. Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA 1985;254:3052-4.
110. Franks AL, Berg CJ, Kane MA, et al. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. N Engl J Med 1989;321:1301-5.
111. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992;89:269-73.
112. Mahoney FJ, Lawrence M, Scott C, Le Q, Lambert S, Farley TA. Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. Pediatrics 1995;96:1113-6.
113. Prevention of transmission of hepatitis B. Can Med Assoc J 1998;159:71-6.
114. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
115. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-6.
116. Preventing hepatitis A infections. National Advisory Committee on Immunization statement. Laboratory Centre for Disease Control. Can Fam Physician 1995;41:1222-8.
117. Linnen J, Wages J Jr, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-8.
118. Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997;336:747-54.
119. Alter MJ, Gallagher M, Morris TT, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl J Med 1997;336:741-6.
120. Frider B, Sookoian S, Castano G, et al. Detection of hepatitis G virus RNA in patients with acute non-A-E hepatitis. J Viral Hepatol 1998;5:161-4.
121. Pessoa MG, Terrault NA, Detmer J, et al. Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology 1998;27:877-80.
122. Berenguer M, Terrault NA, Piatak M, et al. Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology 1996;111:1569-75.
123. Naoumov NV, Petrova EP, Thomas MG, Williams R. Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet 1998;352:195-7.
124. Simmonds P, Davidson F, Lycett C, et al. Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet 1998;352:191-5.
125. Hsieh Sy, Wu YH, Ho YP, Tsao KC, Yeh CT, Liaw YF. High prevalence of TT virus infection in healthy children and adults and in patients with liver disease in Taiwan. J Clin Microbiol 1999;37:1829-31.